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Acupuncture use was nearly six times more common among chiropractic users 
than in the overall population (2.2% vs. 0.37%); similarly, nearly half (42.5%) of 
acupuncture users also had a claim for chiropractic. Over one-in-five patients 
(21.0%) with general joint or back pain used chiropractic, of which 2.65% also 
used acupuncture. CONCLUSIONS: Despite trends suggesting increased use of 
chiropractic and acupuncture, their use remains very low in commercial health 
insurance plans, including patients with inflammation and pain-related 
conditions. While still very low, acupuncture use was more common among 
chiropractic users than in the overall population.  
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GEOGRAPHIC VARIATION TRENDS IN SYSTEMIC LUPUS ERYTHEMATOSUS 
PREVALENCE IN THE UNITED STATES VETERAN POPULATION  
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Ann Arbor, MI, USA  
OBJECTIVES: To examine the geographic, age and racial variation in the 
prevalence of systemic lupus erythematosus (SLE) in the U.S. veteran population. 
METHODS: Patients diagnosed with SLE (International Classification of Disease 
9thRevision Clinical Modification (ICD-9-CM) diagnosis code 710.0) were included 
in a retrospective study (October 1, 2005 - May 31, 2012) conducted using the 
Veterans Health Administration (VHA) Medical SAS Datasets. Disease prevalence 
was stratified by state, age and race for all the patients, and each category was 
then carefully studied. Descriptive statistics were calculated as means ± 
standard deviation (SD) and percentages to measure the prevalence in the 
sample. RESULTS: A total of 13,257 veterans were diagnosed with SLE in 2011. 
For SLE patients between ages 35 and 54, prevalence was the highest at 0.11%, 
followed by patients age 55 to 64 at 0.07%. Patients age 18-25 and 65+ had SLE 
prevalence of 0.03%, and the median prevalence (0.06%) was observed in patients 
age 26-34. Prevalence by race was also examined: Non-Hispanic Black (0.16%), 
Hispanic (0.07%), Non-Hispanic White (0.05%) and other races (0.04%). 
Geographic variation was examined and the highest SLE prevalence was 
observed in Georgia and Alabama (both 0.11%), followed by Arizona, New 
Hampshire, Maryland, Tennessee, Vermont and Virginia (all 0.08%). 
CONCLUSIONS: There is statistical evidence that middle-aged patients have a 
higher probability to be diagnosed with SLE, and younger and elderly patients 
have a relatively smaller probability. Stratified by race, black, Hispanic and white 
patients were more likely to be diagnosed with SLE compared to other races. 
Statistical results also show that patients living in the Southeastern are of the 
United States had a higher risk of SLE diagnosis.  
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THE IMPACT OF RACE ON QUALITY OF ANTICOAGULATION AFTER MAJOR 
ORTHOPEDIC SURGERY IN AN INNER-CITY UNDERSERVED POPULATION  
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OBJECTIVES: The aim of this study was to evaluate the impact of race on quality 
of anticoagulation control in patients undergoing major orthopedic surgery. 
METHODS: We conducted a retrospective, observational cohort study in an 
inner-city underserved population treated with warfarin thromboprophylaxis 
after total hip replacement (THR) or total knee replacement (TKR), referred to a 
specialized antithrombosis clinic from 1998 to 2009. Significant variables from 
simple linear regression (p < 0.1) were entered in stepwise multivariate logistic 
regression (alpha < 0.05) to evaluate the effect of race on quality of 
anticoagulation control, defined as within-patient proportion of international 
normalized ratio (INR) levels spent in therapeutic range (INR of 2-3 ± 0.2). 
RESULTS: A total of 400 consecutive patients were evaluated. The average age 
was 58.4±12.5, 56% were African-American, and 26% were Hispanic. The average 
length of warfarin therapy was 50±21 days, and the average within-patient 
proportion of INR levels spent in therapeutic range was 39.2±20.5%. African-
Americans (β= -8.59, p < 0.0001) had lower within-patient proportion of INR 
levels spent in therapeutic range compared to non-African-Americans. In 
addition, males (β= -5.17, p = 0.0069), higher warfarin dose (β= -3.13, p <0.0001), 
higher frequency of anticoagulation monitoring visits (β= -1.13, p = 0.0214) and 
non-adherence with warfarin (β= -0.31, p <0.0001) were significantly associated 
with a lower proportion of INR levels in therapeutic range. After controlling for 
age, gender, comorbidities, and significant covariates, the effect of African-
American race remained significant (β= -6.90, p = 0.0001). CONCLUSIONS: In this 
inner-city underserved population treated with warfarin thromboprophylaxis for 
THR and TKR, African-Americans tended to have lower proportion of INR levels 
in therapeutic range than non-African-Americans. Studies are needed to further 
elucidate factors driving substandard anticoagulation control in minority 
patients.  
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BUDGET IMPACT OF PREGABALIN FOR THE TREATMENT OF NEUROPATHIC 
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OBJECTIVES: Neuropathic pain (NeP) is a pain caused by a lesion or disease of 
the somatosensory nervous system (International Association for the Study of 
Pain – IASP 2011). In many cases NeP is secondary to herpes zoster infection and 
as a complication of diabetes mellitus. This study aimed to assess the budget 
impact of pregabalin in NeP in adult Colombian population. METHODS: A budget 
impact model was developed with a time horizon of 1 year from the social 
perspective (direct and indirect costs included). Cohort contains 155,030 patients 
over 18 years with NeP, according to Colombian prevalence and considers 20% of 
patients have access to medical treatment. Direct costs (drug acquisition, 
medical visits with general practitioners, specialists and emergency visits) and 
indirect costs (disability payments) of managing patients with neuropathic pain 
were estimated from Colombian sources (tariff manuals and pricing rulings). 
Comparators included those locally approved for NeP: pregabalin (150-300 
mg/day) versus duloxetine (60 mg/day). Univariate deterministic and 
probabilistic sensitivity analyses were done. Costs are in 2012 US$. RESULTS: 
Assuming that each comparator had a 100% market share, the average total 
costs of treating NeP patients for 1 year, with the comparators were: pregabalin 
US $132,965,443 (51.7% drug acquisition, 26.4% medical visits and 21.9% indirect 
costs) and duloxetine US $220,883,844 (68.6% drug acquisition, 14.2% medical 
visits and 17.2% indirect costs). Patients taking pregabalin have a lower 
acquisition cost of drugs. CONCLUSIONS: Pregabalin is a favorable alternative for 
the treatment of NeP compared to duloxetine by saving US $567.1 per 
patient/year compared to duloxetine. Colombian stakeholders should consider 
these findings for future decision-making processes.  
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THE ECONOMIC IMPACT OF INCREASED USE OF MULTI-MODAL ANALGESIA 
FOR THE MANAGEMENT OF POST-SURGICAL PAIN IN THE HOSPITAL SETTING  
Izumi H1, Khangulov V1, Hayashida D1, Peyerl F1, Joysumpoa J2, Lacouture PG2 
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OBJECTIVES: Treating post-surgical patients with opioid and non-opioid 
medications simultaneously can be an effective way to treat pain, minimize 
opioid-associated side-effects, and reduce hospital length of stay (LOS). The 
objective of this exercise was to develop a budget impact model to evaluate the 
economic impact of increased use of multi-modal analgesia following orthopedic 
or abdominal/pelvic surgery in the hospital setting. METHODS: A total of 50,648 
unique patient encounters from a 2009-2012 US electronic health record 
database were evaluated. Patients were segmented into 280 cohorts based on 
surgical procedure (40 unique orthopedic and abdominal/pelvic procedures) and 
NSAID risk factors (7 unique risk groups). Median LOS was calculated for each 
cohort and compared based on analgesia received (opioid-only vs. multi-modal). 
Findings were adjusted to fit the general case of a 250-bed hospital with an 80% 
occupancy rate and performing 3,400 total orthopedic and abdominal/pelvic 
surgeries/year. Median per-day hospital stay costs of $400 and $460 per 
orthopedic and abdominal/pelvic procedure, respectively, were applied. 
RESULTS: Current proportions of patients receiving multi-modal, opioid-only, 
and non-opioid-only therapy were 29.9%, 63.0%, and 7.1%, respectively. Multi-
modal therapy was associated with reduced LOS for 45.2% of cohorts, no change 
in LOS for 41.7% of cohorts, and increased LOS for 13.1% of cohorts. Increasing 
the proportion of patients receiving multi-modal therapy resulted in cost 
savings. Shifting 20% of patients from opioid-only to multi-modal therapy 
resulted in estimated annual savings of $71,526, while shifting 40% of patients in 
this manner reduced costs by $141,317. Conversely, shifting all patients treated 
with multi-modal therapy to opioid-only therapy increased annual costs by 
$105,204. CONCLUSIONS: The model supports the hypothesis that multi-modal 
therapy is associated with reduced LOS and reduced health care costs. While 
currently-available NSAIDs may present their own side-effect risks, NSAIDs with 
improved safety may further reduce costs, assuming similar efficacy and LOS 
effects.  
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THE ECONOMIC BURDEN OF PATHOGEN TRANSMISSION WITHIN THE 
HEMOPHILIA POPULATION OF CHINA  
Zhang M1, Epstein J2, Zhang L3, Chen W3, Zheng W4 
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OBJECTIVES: Hemophilia A is a rare, genetic disorder occurring in males and its 
treatment involves infusing clotting factor concentrate (FVIII). Currently, the 
most widely-used FVIII product in China is plasma-derived FVIII. Since plasma-
derived FVIII is sourced from local blood donations, it is associated with an 
increased risk of blood-borne infection. Blood-borne infections can be life-
threatening and have a significant cost on society. The objective of this study 
was to estimate the extra economic burden associated with a potential blood-
borne infection in the hemophilia population of China. METHODS: An outbreak 
of hepatitis C virus (HCV) was used as a real life example of pathogen 
transmission in the Chinese hemophilia population. Decision tree analysis was 
adopted to calculate the expected life-time incremental cost associated with 
treating hemophilia patients infected with HCV. Costs were discounted and 
sensitivity analyses were conducted to test model sensitivity and assumptions. 
RESULTS: Preventing HCV in hemophilia patients is estimated to save an 
approximately 7 years of life per patient. Expected life-time additional treatment 
cost (FVIII cost not included) of a hemophilia patient infected with HCV was 
estimated at 855,341 RMB. Assuming 10% of the registered Chinese hemophilia A 
patients were affected by HCV, preventing HCV infection in these patients would 
have saved an estimated 774 million RMB in total. CONCLUSIONS: This research 
demonstrates the significant potential economic burden of treating hemophilia 
patients infected with a blood-borne pathogen such as HCV, as well as the value 
of utilizing a FVIII product that eliminates the transmission risk of another 
infectious disease similar to the burden associated with HCV.  
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OBJECTIVES: To evaluate medical and pharmacy costs associated with 
breakthrough pain (BTP) in a commercially-insured population with chronic, 
cancer-related pain. METHODS: The National Breakthrough Pain Survey studied 
a large commercially-insured population using claims data and structured 
interviews to assess the prevalence, characteristics, and impact of BTP. Adult 
patients with ≥2 medical claims at an interval ≥3 months with an ICD-9-CM code 
indicating a chronic pain condition (cancer or noncancer) and ≥3 opioid 
prescription claims consistent with chronic use were eligible. Patients were 
called and interviewed after providing consent; those verifying cancer pain were 
included in this sub-analysis. All-cause medical and pharmacy costs in 2010 US 
dollars were determined from administrative claims data for the 12-month 
period before the survey date. Generalized linear models with gamma 
distribution were constructed because of the skewed nature of the cost data. 
RESULTS: A total of 2198 patients were interviewed, 1279 had controlled 
persistent pain, and 145 of the latter group had cancer pain. Of those with cancer 
pain, BTP was reported by 77.2% (BTP, 112; no BTP, 33). Mean (SD) total annual 
health care costs for patients with and without BTP were $84,049 ($129,279) and 
$77,926 ($98,785), respectively. Costs in patients with BTP were 28.6% higher than 
patients without BTP (P=0.3211) after controlling for health plan, patient 
demographics, comorbidities, history of prior surgery, neuropathic pain, baseline 
pain severity, treatment by a pain specialist, and patient-reported pain 
interference. Mean (SD) total annual pharmacy costs for patients with BTP were 
$20,088 ($35,406) versus $9,939 ($9,715) for patients without BTP. Patients with 
BTP had pharmacy costs that were 81.7% higher than patients without BTP 
(P=0.0265) after controlling for the above variables. CONCLUSIONS: In a 
commercially-insured population, cancer patients with controlled, persistent 
pain and BTP had higher total health care and pharmacy costs than cancer 
patients with controlled, persistent pain without BTP.  
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COST SAVINGS ASSOCIATED WITH FASTER BLEEDING RESOLUTION IN THE 
INPATIENT TREATMENT OF HEMOPHILIA WITH INHIBITORS FOR THE UNITED 
STATES: RFVIIA VERSUS PD-APCC  
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OBJECTIVES: In the United States (US), approximately 862 patients have 
haemophilia with inhibitors. Inpatient hospitalization is often required for 
treatment, which can lead to significant costs to hospitals, depending on the 
cause for hospitalization, and the associated length of stay and hospital resource 
use. Variations in inpatient costs may also depend on patient inhibitor status to 
Factor VIII and the need for treatment with Factor VIII bypassing agents. A US 
hospital-based economic model was developed to estimate inpatient costs for 
on-demand treatment of bleeds of hemophilia patients with inhibitors and to 
quantify potential cost savings. METHODS: An Excel-based model patterned the 
inpatient care associated with use of currently available bypassing agents: 
activated prothrombin complex concentrate (pd-aPCC) and recombinant Factor 
VIIa (rFVIIa) utilizing treatment-specific resource use, service and pharmacy 
costs, and source admission estimates based on a retrospective analysis of the 
Premier Perspective™ Database (1,218 inpatient stays with an ICD-9 diagnosis of 
hemophilia A identified from 2003-2008). RESULTS: Within the Premier analysis, 
from 2003-2008 there were 4,560 male inpatient discharges (unweighted) with a 
Hemophilia A diagnosis. Of these, 252 showed use of a bypassing agent after 
excluding patients with OR charges and patients with inpatient stays with 
charges for both rFVIIa and pd-aPCC. The final weighted sample sizes was 1,218 
inpatient stays. In the base-case analysis, average per-patient costs associated 
with the inpatient treatment of hemophilia with inhibitors were slightly lower 
with rFVIIa as compared with pd-aPCC ($78,086 vs. $78,141). CONCLUSIONS: Fast 
bleed resolution may confer significant inpatient cost savings through 
reductions in length of stay and duration of bypass agent treatment. Thus, rFVIIa 
can reduce overall treatment costs and reduce indirect costs since fewer 
resources are required, which reduces the economic burden of haemophilia on 
society. More comparative studies of these agents for on-demand treatment in 
the inpatient setting are still needed.  
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PARECOXIB VERSUS KETOPROPHENE, KETOROLAC, AND TENOXICAM IN ACUTE 
POST-SURGICAL PAIN MANAGEMENT: A COST-MINIMIZATION ANALYSIS 
FROM THE PRIVATE HOSPITAL PERSPECTIVE IN BRAZIL  
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OBJECTIVES: Anti-inflammatory drugs are widely used in the post-operative 
analgesia. This study aims to compare acute post-surgical pain management 
costs and resource utilization with parecoxib versus ketoprophene, ketorolac, 
and tenoxicam from the perspective of Brazilian private hospitals. METHODS: A 
cost-minimization analysis was performed to compare intravenous parecoxib 
40mg/day (PB), and parecoxib 40mg/day in bolus (PBbl) versus ketoprophene 
100mg/day generic (KPg) and branded (KPb), ketorolac 30mg/day generic (KLg) 
and branded (KLb), and tenoxicam 40mg/day generic (TNg) and branded (TNb), in 
a 3-day hospital stay after an orthopedic surgery. Direct medical costs included 
drug acquisition, nursing fees to administration, infusion supplies, 
complications associated to treatment and adverse event management 
(constipation related to opioid rescue medication, antacid and antiemetic drugs, 
gastrointestinal and surgical-wound bleedings). Resource utilization was 
estimated through literature review and expert opinion. Unit costs were obtained 
from Brazilian official price lists (2012 USD values) for each cost component. 
RESULTS: PBbl was the least costly treatment, with overall costs per patient of 
80.82USD, versus 117.92USD, 173.29USD, 182.56USD, 126.86USD, 133.39USD, 
125.27USD, and 131.67USD, for PB, KPg, KPb, KLg, KLb, TNg, and TNb, 
respectively. Incremental costs of comparators driven by surgical wound and 
gastrointestinal bleeding was responsible for 38.99USD or 22.5%, 21.4%, 30.7%, 
29.2%, 31.1%, and 29.6% with KPg, KPb, KLg, KLb, TNg, and TNb, respectively. No 
bleeding was reported for parecoxib. Adverse event management (antacid, 
antiemetic, constipation) was responsible for 6.37USD(7.9%), 6.37USD(5.4%), 
11.34USD(6.5%), 11.34USD(6.2%), 13.31USD(10.5%), 13.31USD(10.0%), 
8.74USD(7.0%), and 8.74USD(6.6%) with PBbl, PB ,KPg, KPb, KLg, KLb, TNg, and 
TNb, respectively. Drug acquisition, fees and supplies were responsible for 
74.45USD(92.1%), 111.5USD(94.6%), 122.96USD(71.0%), 132.24USD(72.4%), 
74.56USD(58.8%), 81.09USD(60.8%), 77.53USD(61.9%), and 83.93USD(63.7%) with 
PBbl, PB, KPg, KPb, KLg, KLb, TNg, and TNb, respectively. CONCLUSIONS: 
Parecoxib exhibited a cost-saving profile over branded or generic ketoprophene, 
ketorolac, and tenoxicam in post-surgical pain management, from the private 
hospital perspective in Brazil.  
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OBJECTIVES: Estimate the potential impact of opioid analgesics formulated with 
tamper resistant technologies (TRT) on drug acquisition and abuse treatment 
costs in a managed health plan through a budget impact model. METHODS: A 
model was developed to determine the impact of TRT therapy on opioid drug 
costs and abuse treatment costs for a hypothetical health plan of 1 million 
members. Claims analysis from the Thomson Reuters Commercial Encounters 
and Medicare Supplemental database was used to obtain the number of patients 
on low dose oxycodone therapy, annual days supply, prevalence of opioid abuse 
and annual abuse-related treatment costs. Patient willingness to continue TRT 
therapy was obtained from a clinical trial. Patients continuing TRT therapy were 
assumed to be non-abusers. Pricing assumptions were $2.67 (WAC) for a newly 
approved immediate release TRT and $0.16 for generic low dose oxycodone. A 
sensitivity analysis addressed the percentage of abusers placed on TRT therapy. 
RESULTS: Opioid abuse prevalence for patients on low dose oxycodone was 1.8%. 
Mean annual opioid abuse-related medical costs were $5,325. Mean annual days 
supply for patients with abuse claims was 169 days versus 40 days for patients 
with no claims. Thirty percent of patients were not willing to continue TRT 
therapy. With 20% of abuse patients placed on TRT therapy gradually over 24 
months, WAC drug acquisition costs increased 0.6% ($221,697 vs. $217,321) for 
the plan, while abuse treatment costs decreased 1.8% ($500,993 vs. $510,280) and 
total drug and treatment costs decreased 0.7%. With all abuse patients placed on 
TRT therapy, while there was a 3% increase in drug costs, there was a 9.1% 
reduction in abuse treatment costs and a decrease in total drug and treatment 
costs of 3.4%. CONCLUSIONS: TRT for patients with history of opioid abuse can 
potentially result in savings in abuse treatment costs and overall cost reductions.  
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PENICILLIN AND AMOXICILLIN PROPHYLAXIS IN CHILDREN WITH SICKLE CELL 
DISEASE (SCD): COMPLIANCE AND COST COMPARISON  
Zimmermann IR, Alexandre RF, Mosca M, Schneiders RE, do Nascimento Jr JM,  
Gadelha CA 
Ministry of Health, Brasília, DF, Brazil  
OBJECTIVES: To discuss the amoxicillin use as an alternative to penicillin and 
compare its cost for antibiotic prophylaxis in children with SCD. METHODS: We 
searched for evidences in MEDLINE (Pubmed) with the terms “Anemia, Sickle 
Cell”[Mesh] and “Antibiotic Prophylaxis”[Mesh]. In a deterministic fashion, 
adopting the Brazilian public health system perspective, we did a budget impact 
analysis comparing amoxicillin to penicillin. The target population was 
estimated from hidroxyurea consumption in children with SCD and acquisition 
costs, both obtained from Ministry of Health databases (2012 values; exchange 
rate: US$ 1 = R$ 2.04). Data about dosage according to age and bodyweight were 
extracted from literature. RESULTS: A systematic review supports the use of 
penicillin prophylaxis in children with SCD, based on 3 RCTs (OR: 0.37; CI 95%: 
0.16 to 0.86), with no results for amoxicillin. Although, prospective studies show 
a low compliance of this approach (40 to 60%). Comparisons of amoxicillin to 
penicillin in other settings, as rheumatic fever prevention, demonstrate that 
once-daily oral amoxicillin is not inferior to twice-daily penicillin. We estimated 
a range of 143 to 325 children, less than 5 years old, with SCD as our target 
population. Assuming oral daily doses of 1500 mg (or 750 mg if bodyweight less 
than 30 kg) for amoxicillin and 500 mg (or 250 mg if bodyweight less than 20 kg) 
for penicillin, the annual acquisition costs of penicillin, oral solution, to treat this 
population can lead to expenses of US$ 41,161.93 to US$ 93,704.65. In contrast, 
expenses with amoxicillin, oral solution, would be a range of US$ 3,019.94 to US$ 
6,863.49. CONCLUSIONS: As well as penicillin, amoxicillin seems to be a good 
option for preventing pneumococcal infection in children with SCD as its use 
could represent annual savings of US$ 38,141.99 to US$ 86,841.15 and the once-
daily administration could improve the prophylaxis compliance.  
